Update: Supportive PISCES data
ReNeuron presented two-year follow-up data from the PISCES study in disabled stroke patients, which confirm the potential for long-term benefits from treatment with its CTX neural stem cells. Improvements in stroke disability scores observed after 12 months were mostly maintained at 24 months. Beyond CTX, ReNeuron recently filed an IND to commence a Phase I/II study in the US with its human retinal progenitor cells (hRPC) to treat retinitis pigmentosa, an orphan hereditary disease that can lead to blindness, for which no effective treatment options exist.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.